# LB Pharmaceuticals (LBRX) — News

LBRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lbrx/news

## Recent headlines

- [Priced: LBBW EUR 750M 2Y covered MS+7](https://www.ainvest.com/news/priced-lbbw-eur-750m-2y-covered-ms-7-2610) — AInvest Wire, Oct 12, 2026
- [LB Pharmaceuticals reports inducement grants to new employee under Nasdaq listing rule 5635(C)(4)](https://www.ainvest.com/news/lb-pharmaceuticals-reports-inducement-grants-employee-nasdaq-listing-rule-5635-4-2610) — AInvest Wire, Oct 9, 2026
  LB Pharmaceuticals has disclosed inducement grants awarded to a new employee in accordance with Nasdaq Listing Rule 5635(C)(4). The rule permits listed companies to issue equity-based compensation to new employees without shareholder approval, provided the grants are made in connection with the…
- [LB Pharmaceuticals Inc: Canaccord Genuity initiates coverage with buy rating; target price $65](https://www.ainvest.com/news/lb-pharmaceuticals-canaccord-genuity-initiates-coverage-buy-rating-target-price-65-2610) — AInvest Wire, Oct 9, 2026
  Canaccord Genuity has initiated coverage of LB Pharmaceuticals Inc with a "buy" rating and target price of $65 per share. The firm cited the company’s strong product pipeline, recent regulatory approvals, and favorable market positioning as key factors supporting its recommendation. Analysts…
- [LPC: Announces initial public offering of 3,750,000 ordinary shares - SEC filing](https://www.ainvest.com/news/lpc-announces-initial-public-offering-3-750-000-ordinary-shares-sec-filing-2610) — AInvest Wire, Oct 2, 2026
  Louisiana-Pacific Corporation (LPC) has filed with the U.S. Securities and Exchange Commission (SEC) to offer 3,750,000 ordinary shares in an initial public offering. The filing marks the company’s formal step toward a public listing, though details such as pricing range, expected proceeds, and…
- [LB Pharmaceuticals Inc: Needham initiates coverage with buy rating; target price $68](https://www.ainvest.com/news/lb-pharmaceuticals-needham-initiates-coverage-buy-rating-target-price-68-2610) — AInvest Wire, Oct 2, 2026
  LB Pharmaceuticals Inc (NASDAQ:LBRX) has recently drawn attention from analysts at Needham, who have initiated coverage of the stock with a "Buy" rating and target price . This recommendation aligns with broader analyst sentiment, as several firms have maintained positive outlooks on the company in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).